PRINT OUT

Leading Products


Aug 7. 2019
(Â¥ million)

Brand name Active Ingredient Indications Launch
Date
Sales
2017
Sales
2018
Sales 2019
Apr.-Jun. Apr.-Sep.
(estimated)
Annual
(estimated)
Vidaza azacitidine myelodysplastic syndrome Mar-2011 15,643 14,453 3,912 7,500 14,500
Zalutia tadalafil urinary disorder caused by benign prostatic hyperplasia Apr-2014 10,449 12,118 3,401 6,500 13,000
Tramal, Onetram tramadol hydrochloride cancer pain, chronic pain Sep-2010 6,622 7,196 1,940 3,800 7,500
Uptravi selexipag pulmonary arterial hypertension Nov-2016 2,690 4,825 1,566 3,400 7,300
Adcirca tadalafil pulmonary arterial hypertension Dec-2009 4,617 5,173 1,452 2,800 5,400
Cialis tadalafil erectile dysfunction Jul-2009 3,825 4,592 1,073 2,000 3,700
Gazyva obinutuzumab CD20-positive follicular lymphoma Aug-2018 - 1,417 1,014 1,600 3,500
Lunabell norethisterone and ethinylestradiol dysmenorrhea Jul-2008 5,374 4,658 598 1,100 2,000
Azunol Gargle sodium gualenate pharyngitis, tonsillitis, stomatitis, etc. Aug-2002 2,363 2,169 539 900 2,050
Eviprostat herbal extracts benign prostatic hyperplasia Apr-1967 2,761 2,137 499 1,000 1,800
Erizas dexamethasone cipecilate allergic rhinitis Dec-2009 2,916 2,987 396 650 2,700
Profit in co-promotion 3,962 5,057 1,464 2,600 5,800
Revenues from the licensing of industrial 10,378 16,621 3,822 7,800 16,800
Pharmaceuticals 87,416 100,223 25,652 49,600 101,100
Functional Food 14,031 14,492 3,739 7,400 14,900
Net Sales 101,448 114,716 29,391 57,000 116,000

page-top